About 54% of semaglutide users take it to lose weight, per a survey of nearly 15,000 people. 72% of users say they dropped a clothing size.
Recap by typeshit. Full story at CBS News.
General exercise advice aimed at GLP-1 users, shared on Facebook with no study or expert named in the material available.
Gilead takes global rights to the Shanghai biotech's program, led by HCXT-2001, an oral peptide that could compete with injected IBD drugs.
A Facebook promo for a podcast episode on the ripple effects of GLP-1 consumers across businesses. Few details beyond the pitch.
10:49
xitsnemox posts a short check-in from week 14 on oral Wegovy, two weeks after stepping up to the 25mg tablet. A personal account, not medical advice.
Researchers are studying whether the anti-inflammatory effects of GLP-1 receptor agonists could help skin conditions like hidradenitis suppurativa.
Pollock shares five takeaways from the Kittleson et al. guidance, which he says gives heart failure with preserved ejection fraction a real drug regimen.
Loading…